Activist investors have a reputation for shaking things up, pushing companies to rethink strategy, streamline operations, and unlock shareholder value, often giving stocks a noticeable boost. One such buy-rated stock recently catching their attention is Acadia Healthcare (ACHC), which has seen shares struggle amid federal investigations, reimbursement uncertainty, and operational hiccups.
Things got interesting on Sept. 24, when Engine Capital snapped up about 3% of Acadia, sending AHCC stock soaring almost 12% on the same day. In a letter to Acadia’s board, the activist fund called for a board refresh, a review of company assets, and a pause on costly new facility projects. Engine Capital criticized Acadia’s “growth at any cost” approach, which it said had led to poor execution and a bloated corporate structure.
The hedge fund also highlighted that the board lacked a single director with relevant operational experience. Engine Capital suggested Acadia consider selling some assets to generate cash for share buybacks, describing the stock as “deeply undervalued.” So, with activist investors now on board, here’s a closer look at ACHC stock.
Tennessee-based Acadia stands as one of the largest behavioral healthcare providers in the U.S., with a network of more than 260 facilities across 39 states and Puerto Rico. The company runs a wide range of behavioral healthcare facilities, including acute inpatient psychiatric hospitals, residential recovery and eating disorder centers, comprehensive treatment hubs, and residential treatment programs.
The company also operates outpatient clinics, addressing behavioral health and recovery needs across the communities it serves. Its operations include approximately 11,800 beds and a workforce of around 25,000 employees.
Currently valued at about $2.5 billion by market capitalization, shares of this healthcare company have struggled to perform well on Wall Street. Over the past year, ACHC stock has tumbled nearly 52%, even as the broader S&P 500 Index ($SPX) has gained 17%. The weakness has persisted into 2025, with the stock down 32% year-to-date (YTD), compared to a 14% advance for the index. However, momentum has recently begun to swing in Acadia’s favor, with activist pressure sparking renewed optimism. The stock has snapped back 10% in just five trading days, marking a notable shift after its extended slide.
Story Continues
www.barchart.com
After a prolonged downturn, Acadia’s valuation now stands at strikingly low levels. Shares trade at just 10.48 times forward earnings and 0.78 times sales, a steep discount to the sector median multiples. The wide gap highlights how far investor confidence has fallen, but it also suggests meaningful upside if sentiment and fundamentals begin to recover.
Acadia reported its fiscal 2025 second-quarter results on Aug. 5, posting revenue of $869.2 million, up 9.2% from the same period last year and surpassing Wall Street’s forecast of $842.2 million. Same-facility revenue rose 9.5%, fueled by a 7.5% increase in revenue per patient day and a 1.8% rise in patient days, reflecting strong demand across its network.
The company continued to make headway on its growth initiatives, adding 101 beds to existing facilities during Q2, bringing the total to 191 beds added in the first half of 2025. Combined with the 288 beds from newly constructed facilities in Q1, Acadia has added 479 beds year-to-date, strengthening its capacity to serve more patients nationwide.
Acadia also opened four new comprehensive treatment centers (CTCs), bringing the total to 174 CTCs across 33 states. The company now has 21 joint venture partnerships covering 22 hospitals, with 13 operational and nine more slated to open in the coming years, including three later in 2025, expanding its market footprint further.
On the bottom line, adjusted EPS for the quarter came in at $0.83, down 8.8% year-over-year (YOY) but still beating analyst expectations of $0.71. Acadia closed the quarter with $131.4 million in cash and cash equivalents, up from $76.3 million at the end of 2024, and retained $828.3 million in available capacity under its $1 billion revolving credit facility. The company also repurchased $3.2 million in shares during the quarter, demonstrating capital management discipline and confidence in its long-term value.
Looking ahead, Acadia projects full-year 2025 revenue to range between $3.3 billion and $3.35 billion, while adjusted EBITDA is expected to land between $675 million and $700 million. In addition, adjusted EPS for the entire year is projected to range between $2.45 and $2.65.
Even after a bruising stretch for ACHC stock, Wall Street hasn’t completely turned its back on Acadia. The stock currently carries a consensus “Moderate Buy” rating overall, reflecting a mix of optimism and caution among the 15 analysts covering the name. Of those, seven see Acadia as a “Strong Buy,” two lean toward a “Moderate Buy,” five are sitting on the fence with a “Hold,” and just one has a “Strong Sell” rating.
On average, analysts see the stock climbing to $30.29, representing about 12% potential upside from here. However, the most bullish forecast on the Street pegs ACHC stock at $55, implying staggering 104% potential upside from current levels.
www.barchart.com
On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
